Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple Myeloma
Trial Locations (31)

31400

CHU Bordeaux, Bordeaux

Unknown

CHU Amiens Picardie, Amiens

CH d'ANNECY, Annecy

Centre hospitalier d'Argenteuil, Argenteuil

Hopital de la cote Basque, Bayonne

CHU de Besançon, Besançon

Centre hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde

CHU CAEN, Caen

Centre hospitalier Métropole de Savoie, Chambéry

CHU Clermont-Ferrand Site Estaing, Clermont-Ferrand

CHU Henri Mondor, Créteil

Chu Dijon, Dijon

CH Dunkerque, Dunkirk

CHU de Lille, Lille

Groupe hospitalier Bretagne Sud, Lorient

Institut Paoli Calmette, Marseille

CH de METZ, Metz

CHU Saint-Eloi - CHU de Montpellier, Montpellier

Chu de Nantes, Nantes

CHU de Nice, Nice

Hopital Necker, Paris

Hopital saint louis, Paris

CH Perpignan, Perpignan

Hopital Novo, Pontoise

Chu de Rennes, Rennes

Centre Henri Becquerel, Rouen

Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne, Saint-Priest-en-Jarez

Institut de Cancérologie Strasbourg Europe, Strasbourg

CHU Toulouse, Toulouse

CHU de Tours, Tours

CH Bretagne Atlantique, Vannes

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Intergroupe Francophone du Myelome

NETWORK

NCT06062537 - Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter